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Abstract   
Several epidemiological studies support the protective role of breast-feeding in reducing the 
risk for type 1 diabetes. Human breast milk is the perfect nutrition for infants and contains 
many complex proteins, lipids and carbohydrates. In this study, we examined the physiological 
effects of human milk-derived opioid peptides, beta casomorphins (BCM), and compared them 
with bovine milk-derived opioid peptides on pancreatic hormone regulation and -cell 
regeneration. Exposure of wild-type zebrafish embryos to 50 µg/mL of human BCM -5 and -7 
from 3 days post fertilisation until 6 days post fertilisation resulted in an increased insulin 
domain of expression while exposure to bovine BCM -5 and -7 significantly reduced the insulin 
domain of expression as analysed by whole-mount in-situ hybridisation. These changes may 
be accounted for by reduced insulin expression or -cell number and were mitigated by the µ-
opioid receptor antagonist, naloxone. The effect of BCM on -cell regeneration was assessed 
following ablation of -cells in Tg (ins: CFP-NTR) zebrafish from 3 days post fertilisation to 
4 days post fertilisation, followed by exposure of bovine and human BCM -5 and -7 (50 µg/mL) 
from 4 days post fertilisation until 7 days post fertilisation. The regenerative capacity of -cells 
was not impeded following exposure to human BCM -5 and -7, whereas the capacity of -cells 
to regenerate following bovine BCM -5 and -7 exposure was reduced. Our data suggests that 
human BCM -5 and -7 may promote -cell development and enable the regeneration of -cells, 
while the bovine milk derived peptides, BCM -5 and -7 play an opposite role. These data may 
provide some biological explanation for the protective effect of breastfeeding on the 
development of Type 1 Diabetes.  
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Abbreviations  
AAA Amino acid analysis 
BB BioBreeding 
bBCM-5 Bovine beta-casomorphin 5 
bBCM-7  Bovine beta casomorphin 7 
BCM-7 Beta casomorphin 7 
Cfp Cyan fluorescent protein 
Dpf  Days post fertilisation  
hBCM-5 Human beta-casomorphin 5 
hBCM-7 Human beta-casomorphin 7 
Hpf Hours post fertilisation  
MTZ Metronidazole 
NOD Non obese diabetic 
PBTween Phosphate buffered saline with Tween® 20 
PFA Paraformaldehyde  
T1D Type 1 diabetes 
WISH Whole-mount in-situ hybridisation 
WT Wild-type 
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Introduction 
The incidence and prevalence of Type 1 diabetes (T1D) has increased worldwide over the past 
2-3 decades (1, 2). Although certain genetic traits are associated with T1D (3, 4), the influence 
of environment is evidenced by the observation that migrants acquire the same risk of T1D as 
the populations in the new area of residence (5, 6).  Viral infections (7), lifestyle factors, 
antibiotic use and dietary factors (2, 6, 8, 9) have all been  implicated in the increasing incidence 
of T1D. Combined with permissive gut factors such as abnormal mucosal immunity, local 
inflammation or altered gut permeability (10),  triggers operational early in life may produce 
autoantibodies in children with a genetic susceptibility to T1D (11).  
Breast milk is the first source of nutrition for many newborns and the World Health 
Organization (WHO) recommends, “mothers exclusively breastfeed infants for the child's first 
six months to achieve optimal growth, development and health. Thereafter, they should be 
given nutritious complementary foods and continue breastfeeding up to the age of two years or 
beyond” (12). Lund-Blix and colleagues examined feeding practices in Norway and Denmark 
and showed that infants that had never been breastfed had a two-fold increase in T1D, implying 
that breastfeeding might play a protective role in the relationship between dietary factors and 
T1D (13, 14). The mechanism underpinning these observations however are unknown.  
Human milk contains biologically active substances including the beta-casomorphin (BCM) 
peptides. Both human and bovine milk-derived beta casomorphins (hBCM and bBCM) have 
been reported to have opioid properties (15, 16). bBCM -5 (Tyr-Pro-Phe-Pro-Gly) and -7 (Tyr-
Pro-Phe-Pro-Gly-Pro-Ile), and hBCM-5 (Tyr-Pro-Phe-Val-Glu) and -7 (Tyr-Pro-Phe-Val-Glu-
Pro-Ile) are obtained as a result of C-terminal cleavage of the parent beta-casein protein by 
proteolytic degradation in the gut (17). These peptides are nearly identical except for the 
substitution of (Val-Glu) at positions 54 and 55 of the human beta-casein, with (Pro-Glu) at 
positions 63 and 64 in the bovine beta-casein (18). We hypothesized that these differences 
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between human and bovine BCM peptide sequence would differentially affect -cell biology 
and thus the aim of this study was to examine the effect of hBCM on β-cell development and 
regenerative capacity and compare with bBCM.  
We utilised zebrafish to compare the effect of hBCM to bBCM on the β-cell biology as 
zebrafish embryos offer unique advantages for the study of diabetes. The zebrafish pancreas 
share its basic organization and cell types with the mammalian pancreas (19). Like the 
mammalian pancreas the zebrafish is composed on an exocrine and endocrine pancreas with 
alpha, beta, delta, epsilon and pp cells (20). The zebrafish pancreas starts developing from 24 
hours post fertilisation (hpf), and β-cells start expressing insulin as early as 15 hpf (21). The 
zebrafish endocrine function of glucose homeostasis is highly conserved between zebrafish and 
mammals (22). However, zebrafish offer a unique advantage for the study of diabetes and one 
that lost in mammals: they can regenerate after ablation or injury without the need of external 
stimuli (23).  
In addition, we utilised the Tg (ins: CFP-NTR) zebrafish embryos that permit the preferential 
ablation, as well as direct visualisation, of the β-cells tagged with cyan fluorescent protein 
(CFP) (24). Using these embryos, the effect of hBCM-5 and -7 and bBCM-5 and -7 on the 
regenerative capacity of the β-cells was determined. 
Results 
Human BCMs augment the domain of expression of insulin  
To determine the effect of BCM on β-cell biology, WT embryos were exposed to bovine and 
human BCM-5 and -7 from 3 until 6 dpf and analysed by WISH. Exposure to bBCM-5 and -7 
resulted in a significant decrease in the insulin domain of expression (n=20, p<0.05), while 
exposure to hBCM-5 and -7 significantly increased the insulin domain of expression (n=20, 
p<0.005) as compared to untreated controls (Fig. 1.1 and Fig. 1.2). These data suggest that 
B
io
lo
gy
 O
pe
n 
• 
A
cc
ep
te
d 
m
an
us
cr
ip
t
BCMs may impact the insulin domain of expression by either modulating β-cell number or 
function.  
The glucagon domain of expression was increased (n=10, p<0.05) following bBCM-7 
treatment, while no change was observed with bBCM-5, hBCM-5 and -7. No significant 
change in the somatostatin domain of expression was observed (Fig. 2.1 and Fig. 2.2) in any 
group. These data demonstrate that BCMs primarily affect the domain of expression of insulin 
suggesting that the main effect is on β-cells.  
The effect of BCMs on insulin expression is mediated via the µ-opioid receptor 
BCMs act via the µ-opioid receptors (25, 26), which are located on pancreatic β-cells (27). The 
µ-opioid receptor in zebrafish shares close functional similarities with the mammalian µ-opioid 
receptor (28). WT zebrafish embryos were pre-treated with the µ-opioid receptor antagonist 
naloxone. The changes in the domain of expression of insulin induced by treatment with human 
and bovine BCM were mitigated with exposure to naloxone with levels approaching that of 
untreated controls (Fig. 3.1 and Fig. 3.2). These data indicate that the effects of BCMs on beta 
cell biology are mediated via the µ-opioid receptors.  
β-cell regenerative capacity is unimpeded by human BCM -5 and -7  
β-cells retain the potential to proliferate and regenerate under pathophysiological conditions 
including T1D (reviewed by Wu et al (29)). To determine whether BCMs affect β-cell 
regeneration Tg (ins: CFP-NTR) embryos were treated with MTZ to ablate the β-cells and then 
exposed to BCMs. 
Treatment with 12 mM MTZ completely ablated β-cells in Tg (ins: CFP-NTR) embryos (Fig. 
D. 1), which had regenerated at 7 dpf (Fig. 4.2). Embryos treated with bBCM-5 and -7 
following ablation showed a significantly reduced area of CFP fluorescence at 7 dpf compared 
to control zebrafish embryos (n=20, p<0.0005) (Fig. 4.2 and Fig. 4.3) indicating that the 
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number and/or size of the β-cells was decreased. The area of fluorescence observed with Tg 
(ins: CFP-NTR) embryos treated with hBCM-5 and -7 at 7 dpf (n=20, p>0.1) was similar to 
controls (Fig. 4.1 and Fig. 4.2). These data suggest that bBCM-5 and -7 negatively impacted 
the regenerative potential of β-cells, whereas hBCM-5 and -7 allowed β-cell regeneration to 
proceed.  
 
 
Discussion  
T1D is an autoimmune disease, triggered by an exposure to one or more environmental risk 
factor in a genetically susceptible individual (30). T1D is a disease of the young suggesting 
that the influencing environmental triggers are operational early in life (31). As exclusive 
breastfeeding is the recommended dietary source for the first 6 months of life, we sought to 
investigate if the human milk-derived bioactive peptides hBCM-5 and -7 may influence β-cell 
biology. Our data showed that the hBCM-5 and -7 promoted the domain of expression of 
insulin in β-cells during development, which was mediated via the µ-opioid receptor. We also 
demonstrated that hBCM-5 and -7 did not impede β-cell regeneration following ablation.  
These data are distinct to the effects of bBCM-5 and -7, which reduced the insulin domain of 
expression and retarded β-cell regeneration. It is possible that BCM peptides modulated insulin 
expression or had a direct effect on -cell number to cause this effect and quantification of β-
cell number will be required to determine the predominant effect.  
It is intriguing that human and bovine BCMs induced opposing effects on the insulin domain 
of expression in WT embryos and yet the effects of both were neutralised with naloxone 
treatment. Naloxone is a competitive opioid antagonist with the highest affinity for the μ 
receptor but with activity at other opioid receptors. These data suggest that both forms of BCMs 
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signal through opioid receptors on the -cell yet with divergent effects. Human islets express 
mRNAs for δ, and μ and NOP opioid receptors (32). Activation of the Gi-coupled δ and μ 
receptors inhibits insulin release and stimulates glucagon release in vivo in humans  (33) and 
is consistent with what was observed in response to bovine BCM, in particular bBCM-7, 
suggesting that these receptors may be involved in the observed effect. In contrast, human 
BCM-5 and -7 increased the insulin domain of expression without an effect on glucagon 
expression.  It is possible that human BCM is signalling via alternate opioid receptors, such as 
NOP, in which data on the effect on islet hormone secretion is lacking (32). It is also worthy 
to note that G-protein coupled receptors, including opioid receptors, undergo homo and 
heterodimerization. Receptor dimerization can influence the potency of agonists (34) as well 
as downstream signalling pathways and may be operational in the effect of human BCM on -
cell biology in this instances (35).  
Furthermore, bovine BCMs retarded -cell regeneration whereas those exposed to hBCMs 
proceeded unhindered, although were not augmented. Blocking experiments were not 
conducted and thus it is assumed here that bovine BCMs are signalling via δ and/or μ receptors 
inhibiting -cell regeneration. In this instance the possible alternate opioid receptor signalling 
of human BCMs has no effect on regenerative capacity of -cells. 
Debate around the role of breastfeeding and onset of T1D has existed for decades. Paronen and 
colleagues highlighted the protective effects of breastfeeding on the incidence of T1D (36). 
The study concluded that infants with an increased genetic risk of developing T1D and 
exclusively breastfed had no IgG antibodies to insulin, while infants exposed to cow’s milk 
develop IgG antibodies to bovine insulin (36). Similarly, the Norwegian Environmental 
Triggers of Type 1 Diabetes study (MIDIA) demonstrated a protective association of 
breastfeeding (37), which was independent of the duration of breastfeeding (38). Several other 
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epidemiological studies highlight the protective effect of breastfeeding in lowering the risk of 
T1D (13, 39-41). However, the data is conflicting. Hakola et al explored the associations 
between food diversity in infancy and the risk of islet autoimmunity or type 1 diabetes.  In a 
sub analysis they showed shorter breastfeeding duration was associated with increased risk of 
advanced islet autoimmunity but not Type 1 Diabetes concluding that the protective effect of 
breastfeeding was weak (42). 
Breastfeeding has inherent physiological advantages for the infant with the composition of 
breastmilk changing in parallel with infant growth and nutritional needs. Breast milk provides 
protection for the newborn gut, stimulates the neonates immune system and reduces 
inflammation (43). Biologically active opioid peptides like BCMs are thought to lead to 
calmness and sleep in infants (44), normal psychomotor development and muscle tone (45). 
hBCM-5 and -7 are present at elevated levels in the human colostrum (46) suggesting an 
important role in physiological processes in newborn (47).  
Our data demonstrates a previously unknown direct effect on β-cells of the bioactive peptides 
from human milk, hBCM-5 and -7, which may play an important role in the early infant 
pancreatic development. Several β-cell mitogens and cellular pathways have been proposed to 
enhance β-cell regeneration in experimental animal models (48). Although the exact 
mechanisms that regulate the β-cell regeneration are poorly understood, it is widely accepted 
that the β-cell mass has a degree of plasticity and may fluctuate in response to physiological 
stress (49).  
The role of cows’ milk in the incidence of T1D remains controversial. Elliot and Laugesen in 
a large epidemiological study showed that that incidence of T1D and ischaemic heart disease 
was higher in countries with a higher consumption of cow’s milk (50). Furthermore, several 
claims about the association of cows’ milk proteins and the immunogenic determinants of T1D 
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(51-53) have generated significant public interest (54). We recently demonstrated that 
genetically susceptible non-obese diabetic (NOD) mice fed a diet supplemented with A1 beta-
casein have an increased prevalence of diabetes compared to NOD mice fed with A2 beta 
casein diet in which the BCM7 shares similarities with hBCM7 (55). The mechanisms 
underpinning these observations however remain elusive. In this study, the insulin domain of 
expression in zebrafish embryos decreased following exposure to bBCM-5 and -7, which may 
reflect a reduction in β-cell size or number. Decreased insulin levels following exogenous 
opioid administration have been observed and thought to be a consequence of insulin signalling 
inhibition as a result of a direct cross-talk between the µ-opioid receptor and the insulin 
signalling cascade (56, 57).  
Human breast milk is recognised as the ideal first food and the best source of nutrition for 
newborns. Here, we have identified a previously unknown function of human milk derived 
biologically active BCM peptides in insulin regulation and β-cell mass regeneration. These 
data indicate that breastfeeding may be advantageous to β-cell biology.  
Materials and methods 
Zebrafish maintenance  
All animal husbandry and experimental protocols complied with the Deakin University animal 
ethics committee (AWC G17-2015). Embryos were obtained from wild-type (WT) and Tg (ins: 
CFP-NTR) zebrafish adults and raised in embryonic media (E3) under standard conditions at 
28.5°C with a 14 h light/10 h dark cycle, and staged according to standard procedures (58).  
Analysis of beta cell development following beta-casomorphin exposure 
Bovine and human beta-casomorphin -5 and -7 were purchased from Australian Biobest 
Biotechnology Service and characterised by amino acid analysis (AAA) (refer Table S1). WT 
zebrafish embryos were exposed to 50 µg/mL of bovine and human BCM -5 and -7 (in vehicle, 
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E3) every 24 h from 3 until 6 days post fertilisation (dpf). At 6 dpf, WT embryos were 
humanely killed using 0.04% tricaine solution and fixed overnight in 4% paraformaldehyde 
(PFA) at 4 °C. The embryos were stored in 100% methanol for at least 24 h at -20°C. Whole-
mount in-situ hybridisation (WISH) was performed according to established methodology (59) 
using insulin, glucagon and somatostatin mRNA probes (60). The domain of expression 
(positively stained area in the zebrafish embryo) was measured using Fiji (software) and fold 
change (relative to untreated control) calculated. 
Analysis of the opioid receptor-mediated effects on insulin regulation by beta 
casomorphins  
WT zebrafish embryos were pre-treated with 10 µM naloxone (in vehicle) for 2 h at 3 dpf. 
Following pre-treatment, embryos were exposed to daily 24 h treatments of 50 µg/mL of 
bBCM-5, -7 and hBCM-5, -7 from 3 until 6 dpf. In addition, 10 µM naloxone was also added 
daily to the treatment mixture from 3 until 6 dpf. Control zebrafish remained in vehicle only 
under identical conditions. The embryos were humanely killed using 0.04% tricaine solution, 
fixed overnight at 4°C using 4% PFA, and stored in 100% methanol at -20°C. Insulin domain 
of expression following WISH was measured using Fiji (software) and fold change calculated. 
Analysis of the regenerative capacity of β-cells following ablation and BCM exposure 
Tg (ins: CFP-NTR) zebrafish embryos were treated with 12 mM metronidazole (MTZ) in 
vehicle for the conditional ablation of beta cells from 3 dpf until 4 dpf. Following β-cell 
ablation, embryos were exposed to daily 24 h treatments of 50 µg/mL of bBCM-5, -7 and 
hBCM-5 and -7 from 4 dpf until 7 dpf. Untreated Tg (ins: CFP-NTR) (Unablated control) 
zebrafish embryos remained in vehicle from 0 hpf until 7 dpf. MTZ treated control Tg (ins: 
CFP-NTR) (Ablated control) zebrafish embryos were transferred to vehicle alone after β-cell 
ablation from 3 until 4 dpf and remained in vehicle until 7 dpf.  The embryos were humanely 
killed at 7 dpf using 0.04% tricaine solution and fixed overnight at 4°C using 4% PFA. Fixed 
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embryos were rinsed thrice in 1X Phosphate buffered saline with Tween® 20 (PBTween) for 
2 min each. Embryos were incubated in 30% and 50% glycerol/PBTween (10 min each) and 
stored in 70% glycerol/PBTween at 4°C. Embryos were mounted in 70% glycerol/PBTween 
and imaged using ZOE™ fluorescent cell imager (Bio-Rad). Statistical analysis 
(quantification) of the regenerated β-cells was performed by measuring the area with CFP 
fluorescence (positive indication of beta cells) in the zebrafish embryos using Fiji (software) 
and fold change (compared to MTZ treated controls) calculated. Significance of the results was 
calculated using the Student’s t-test. 
Bovine and human BCM peptide amino acid analysis (AAA): AAA was performed by the 
Australian Proteome Analysis Facility (Macquarie University, Sydney, New South Wales, 
Australia) to determine the composition and concentration of the synthetic, bovine and human 
BCM-5 and -7 peptides. 
The bovine and human BCM -5 and -7 peptides with a minimum purity of 98% were obtained 
from the Australian Biobest Biotechnology Service, Australia 
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Figures 
 
 
Fig. 1. Whole-mount in-situ hybridisation to analyse the effect of chronic beta-casomorphin 
exposure on insulin domain of expression. (1). Insulin domain of exposure (black arrowheads) 
in WT zebrafish embryos exposed to 50 µg/mL of bBCM-5, bBCM-7, hBCM-5 and hBCM-7 
from 3 dpf until 6 dpf. (2). Statistical analysis of insulin domain of expression using Student’s 
t-test. Fold change (compared to untreated control zebrafish embryos) shows insulin domain 
of expression significantly decreased following bBCM-5, -7 exposure and significantly 
increased following hBCM-5, -7 exposure. Data represents Mean ± SEM; *p < 0.05, **p < 
0.005; Student t-test. (n=20). WT, wild-type; bBCM-5, bovine beta-casomorphin 5; bBCM-7, 
bovine beta-casomorphin 7; hBCM-5, human beta-casomorphin 5; hBCM-7, human beta-
casomorphin 7; dpf, days post fertilization.  
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Fig. 2. Whole-mount in-situ hybridisation to analyse the effect of chronic beta-casomorphin 
exposure on glucagon and somatostatin domain of expression. (1) Glucagon (black 
arrowheads) and somatostatin (black arrows) domain of exposure in WT zebrafish embryos 
exposed to 50 µg/mL of bBCM-5, bBCM-7, hBCM-5 and hBCM-7 from 3 dpf until 6 dpf. (2). 
Statistical analysis of glucagon and somatostatin domain of expression using Student’s t-test. 
Fold change (compared to untreated control zebrafish embryos) shows glucagon domain of 
expression significantly increased following bBCM-7 exposure. No significant change in 
glucagon and somatostatin domain of exposure was detected following bBCM-5, hBCM-5 and 
-7 exposure. Data represents Mean ± SEM; *p < 0.05; Student t-test. (n=10). WT, wild-type; 
bBCM-5, bovine beta-casomorphin 5; bBCM-7, bovine beta-casomorphin 7; hBCM-5, human 
beta-casomorphin 5; hBCM-7, human beta-casomorphin 7; dpf, days post fertilization.  
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Fig. 3. Whole-mount in-situ hybridisation analysis of the opioid nature of the beta 
casomorphins. (1) WT zebrafish embryos were pre-treated with 10 μM naloxone for 2 h to 
block the μ-opioid receptors and exposed to naloxone and 50 µg/mL of bBCM-5, bBCM-7, 
hBCM-5 and hBCM-7 every 24 h from 3 dpf until 6 dpf. (Black arrowheads represent the 
insulin domain of expression). (2) Statistical analysis of the insulin domain of expression using 
Student’s t-test. Fold change (compared to untreated control zebrafish embryos) shows insulin 
domain of expression significantly decreased following bBCM-5, -7 exposure and significantly 
increased following hBCM-5, -7 exposure. WT embryos treated with µ-opioid receptor 
antagonist, naloxone and bBCM-5, -7 and hBCM-5, -7 showed no changes in the insulin 
domain of expression compared to untreated controls.  Data represents Mean ± SEM; *p < 
0.05, **p < 0.005; Student t-test. (n=20). WT, wild-type; bBCM5, bovine beta-casomorphin 5; 
bBCM7, bovine beta-casomorphin 7; hBCM5, human beta-casomorphin 5; hBCM7, human 
beta-casomorphin 7; dpf, days post fertilization.  
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Fig. 4. Effect of beta-casomorphins on beta cell regeneration. (1) Beta cell ablation in Tg (ins: 
CFP-NTR was performed using 12 mM MTZ from 3 dpf until 4 dpf. No positively fluorescent 
cells were detected at 4 dpf indicating complete ablation (black arrowheads indicate beta cells).  
(2) Tg (ins: CFP-NTR) zebrafish embryos were treated with 12 mM MTZ from 3 dpf until 4 
dpf to ablate the pancreatic beta and exposed to daily 24 h treatments of bBCM-5, bBCM-7, 
hBCM-5 and hBCM-7 from 4 until 7 dpf to analyse the effects of beta-casomorphins on beta 
cell regeneration (black arrowheads indicate beta cells). (3) Statistical analysis using Student’s 
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t-test revealed a significant decrease in the area of CFP fluorescence (measured using Fiji) 
following treatment with bBCM-5 and bBCM-7 compared to ablated controls at 7 dpf. No 
changes were detected in the area of CFP fluorescence following treatment with hBCM-5 and 
hBCM-7 compared to ablated controls at 7 dpf. Data represents Mean ± SEM; *p<0.0005; 
Student t-test. (n=20). bBCM5, bovine beta-casomorphin 5; bBCM7, bovine beta-casomorphin 
7; hBCM5, human beta-casomorphin 5; hBCM7, human beta-casomorphin 7; dpf, days post 
fertilization.  
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